FHND-9041
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for FHND-9041, covering 2024-07-25 to 2024-07-25. Get the full timeline:
Most recent: Clinical Trial Update: First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]